The Orange Book Patent of Dymista: A Comprehensive Overview

H1. Introduction

Dymista is a nasal spray medication used to treat allergic rhinitis, a common condition characterized by sneezing, runny nose, and congestion. Developed by Meda Pharmaceuticals, Dymista contains a unique combination of azelastine hydrochloride and fluticasone propionate. In this article, we will delve into the Orange Book patent of Dymista, exploring its patent history, expiration dates, and implications for the pharmaceutical industry.

H2. What is the Orange Book?

The Orange Book, officially known as the Approved Drug Products with Therapeutic Equivalence Evaluations, is a publication of the United States Food and Drug Administration (FDA) that lists approved drug products, including their patents and exclusivities. The Orange Book serves as a valuable resource for pharmaceutical companies, researchers, and healthcare professionals to stay informed about the patent landscape of approved medications.

H3. Dymista's Patent History

Dymista's patent history dates back to 2007, when Meda Pharmaceuticals filed a New Drug Application (NDA) with the FDA for the nasal spray. The company's patent application, US Patent 8,557,451, was granted in 2013, covering the composition of matter for azelastine hydrochloride and fluticasone propionate in a nasal spray formulation.

H4. Patent Expiration Dates

According to the Orange Book, the patent for Dymista's composition of matter (US Patent 8,557,451) expires on September 15, 2028. Additionally, Meda Pharmaceuticals has filed for a patent extension under the Hatch-Waxman Act, which could potentially extend the patent protection for Dymista beyond 2028.

H2. Exclusivity and Market Impact

The patent expiration date for Dymista's composition of matter has significant implications for the pharmaceutical industry. As the patent expires, generic versions of the medication may enter the market, increasing competition and potentially driving down prices. This could lead to increased market share for generic manufacturers and reduced revenue for Meda Pharmaceuticals.

H3. Generic Challengers

Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA to market generic versions of Dymista. These generic challengers include:

* Teva Pharmaceuticals (ANDA 208,445)
* Sandoz (ANDA 208,446)
* Mylan Pharmaceuticals (ANDA 208,447)

H4. Patent Disputes

In 2020, Meda Pharmaceuticals filed a patent infringement lawsuit against Teva Pharmaceuticals, alleging that the generic manufacturer's ANDA infringed on the company's patent for Dymista's composition of matter. The lawsuit is ongoing, and its outcome will have significant implications for the pharmaceutical industry.

H2. Conclusion

The Orange Book patent of Dymista provides valuable insights into the patent landscape of approved medications. As the patent expiration date approaches, generic manufacturers are preparing to enter the market, increasing competition and potentially driving down prices. The implications of this patent expiration date will be significant for Meda Pharmaceuticals and the pharmaceutical industry as a whole.

H3. Key Takeaways

* The patent for Dymista's composition of matter expires on September 15, 2028.
* Meda Pharmaceuticals has filed for a patent extension under the Hatch-Waxman Act.
* Several generic manufacturers have filed ANDAs to market generic versions of Dymista.
* Patent disputes are ongoing between Meda Pharmaceuticals and generic manufacturers.

H4. FAQs

1. Q: What is the Orange Book?
A: The Orange Book is a publication of the FDA that lists approved drug products, including their patents and exclusivities.

2. Q: What is the patent expiration date for Dymista's composition of matter?
A: The patent expires on September 15, 2028.

3. Q: Who has filed ANDAs to market generic versions of Dymista?
A: Teva Pharmaceuticals, Sandoz, and Mylan Pharmaceuticals have filed ANDAs.

4. Q: What is the outcome of the patent dispute between Meda Pharmaceuticals and Teva Pharmaceuticals?
A: The lawsuit is ongoing.

5. Q: What are the implications of the patent expiration date for Meda Pharmaceuticals and the pharmaceutical industry?
A: The patent expiration date will lead to increased competition and potentially drive down prices.

Sources:

1. DrugPatentWatch.com. (2022). Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray. Retrieved from <https://www.drugpatentwatch.com/drug/dymista-azelastine-hydrochloride-and-fluticasone-propionate-nasal-spray>
2. FDA. (2022). Orange Book. Retrieved from <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. Meda Pharmaceuticals. (2022). Dymista. Retrieved from <https://www.meda.com/dymista>
4. Teva Pharmaceuticals. (2022). Teva Pharmaceuticals Files ANDA for Dymista. Retrieved from <https://www.tevapharm.com/news/teva-pharmaceuticals-files-anda-for-dymista>
5. Sandoz. (2022). Sandoz Files ANDA for Dymista. Retrieved from <https://www.sandoz.com/news/sandoz-files-anda-for-dymista>